Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Abbott Laboratories (ABT)

Abbott Labs adds Kevin Conroy to board, expands it to 13, approves 2026 incentive plan

Neutral Impact 3 of 5 shareholder Written later

At its April 24, 2026 annual meeting, Abbott shareholders approved a new 2026 Incentive Stock Program, which replaces the 2017 program and authorizes up to 140,000,000 shares plus returned 2017 program shares. The board also added Kevin Conroy as a director and increased its size from twelve to thirteen seats, while all 12 nominees were re-elected by shareholders.

Key points

  • Kevin Conroy named to the Board of Directors on April 24, 2026; board size raised from 12 to 13 persons
  • Shareholders approved the 2026 Incentive Stock Program with 95.82 percent of votes cast in favor
  • Shareholders approved the advisory executive compensation vote with 90.35 percent in favor and ratified Ernst & Young LLP as auditors

The filing

CompanyAbbott Laboratories (ABT)
Form8-K, current report
Filed with the SECApr 27, 2026, 4:06 PM ET
Accession number0001104659-26-049434

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.